Randomized trial shows bismuth-doped bioglass amplifies cancer treatment effects in bone malignancies, indicating potential for improved healing.
With the aim to improve local cancer radiotherapy while maintaining the tissue-regenerative properties of the glass, bioglasses with the composition (58 − x )SiO 2 –36CaO–6P 2 O 5 – x Bi 2 O 3 (where x = 0, 2, 5, or 10 wt%) were synthesized using the sol-gel method. The obtained glasses were labeled as BG, 2Bi-BG, 5Bi-BG, and 10Bi-BG, respectively. Numerous characterization techniques, including XRD, FTIR, SEM-EDX, and DLS were utilized. MTT, fluorescence microscopy, and flow cytometry were used to assess biocompatibility, osteointegration, and sensitization enhancement ratio (SER), respectively, after bismuth addition. A broad hump centered at 12° 2θ, indicating the amorphous, glassy nature of the products. Doped samples showed additional weak reflections confirming the presence of Bi 2 O 3 and quantifying its proportion within the material. Zeta potential measurements revealed values ranging from − 11.9 to − 14.2 mV ( p < 0.01) with increasing bismuth content. This may have influenced cell behavior, specifically adhesion. In vitro, three-times more osteoblasts adhere to 10Bi-BG surfaces than BG surfaces. Bioactivity, in terms of apatite formation ability, was verified in vitro through immersion in SBF. Finally, combining 10Bi-BG with radiation significantly induced greater cell death than radiation alone. The SER of 10Bi-BG was approximately 2.6. Consequently, bismuth-doped 58 S bioglasses represent a promising bifunctional platform capable of simultaneously amplifying localized radiotherapy efficacy and stimulating bone tissue regeneration in the comprehensive management of bone malignancies.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: